scholarly journals Long-term administration of high doses of transdermal buprenorphine in cancer patients with severe neuropathic pain

2015 ◽  
pp. 3621 ◽  
Author(s):  
Wojciech Leppert ◽  
Grzegorz Kowalski
Keyword(s):  
Neuropathic Pain ◽  
Cancer Patients ◽  
Term Administration ◽  
High Doses

Effects of long-term administration of high doses of medroxyprogesterone acetate on hormone receptors and target organs in the female rat

1984 ◽  
Vol 103 (3) ◽  
pp. 287-293 ◽  
Author(s):  
F. Di Carlo ◽  
S. Racca ◽  
G. Conti ◽  
E. Gallo ◽  
G. Muccioli ◽  
...  
Keyword(s):  
Pituitary Gland ◽  
Medroxyprogesterone Acetate ◽  
Prolactin Receptor ◽  
Female Rats ◽  
Serum Prolactin ◽  
Target Organs ◽  
Term Administration ◽  
Pituitary Glands ◽  
High Doses

ABSTRACT The changes in oestrogen, progesterone and prolactin receptor levels in target organs, and the macroscopic and microscopic modifications of uterus, ovary, adrenal and pituitary gland induced by long-term administration of high doses of medroxyprogesterone acetate (MPA) were investigated in female rats. Medroxyprogesterone acetate was injected i.m. for 30 days at daily doses of 7·5, 15 and 75 mg/kg. Oestrogen and/or progesterone-binding capacities were remarkably reduced at all doses of MPA used both in the uterus and pituitary gland. Furthermore, MPA caused a very evident reduction in the weight of pituitary glands, ovaries, adrenals and uterus. In all MPA-treated rats corpora lutea were absent from the ovaries, whereas the adrenals showed a significant reduction in the thickness of the cortex. In accordance with this, there was no evidence of ACTH-producing cells in the pituitary glands. Prolactin-producing cells were also absent, while GH-producing cells were present. Serum prolactin levels were significantly reduced at all doses of MPA used. A dramatic reduction of prolactin receptor concentrations was observed in the liver and the ovaries of MPA-treated rats. The results suggest that MPA acts as an antioestrogenic drug both by reducing the number of oestrogen receptors in target tissues and by changing the structure (and perhaps the function) of those organs (pituitary glands, ovaries and adrenals) which are, directly or indirectly, a source of oestrogens. The decreased synthesis of prolactin and the reduction of the number of prolactin receptors (which, on the contrary, are both increased by oestrogens) might be considered as additional antioestrogenic effects of MPA. J. Endocr. (1984) 103, 287–293

Safety of Long-Term Administration of Bisphosphonates in Elderly Cancer Patients

Oncology ◽  
2004 ◽  
Vol 67 (2) ◽  
pp. 112-116 ◽  
Author(s):  
Paolo Tralongo ◽  
Lazzaro Repetto ◽  
Anna Di Mari ◽  
Gaetano Mauceri ◽  
Roberto Bollina ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Elderly Cancer Patients ◽  
Term Administration

Matrix metalloproteinases 9 and 14 polymorphisms and long-term complications in surgically treated breast cancer patients.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e24074-e24074
Author(s):  
Nikola Besic ◽  
Katja Goricar ◽  
Petra Piber ◽  
Neza Vavpetic ◽  
Vita Dolzan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Wound Healing ◽  
Neuropathic Pain ◽  
Matrix Metalloproteinases ◽  
Cancer Patients ◽  
Breast Cancer Surgery ◽  
Breast Cancer Patients ◽  
Wild Type ◽  
Matrix Metalloproteinases 9

e24074 Background: Matrix metalloproteinases (MMPs) are zinc-containing endopeptidases that are involved in tissue remodeling. They can regulate interactions of cells with extracellular matrix and can play a role in wound healing. High levels of metalloproteinases have been correlated with significantly delayed wound healing in wounds of a variety of etiologies. The aim of our present study was to evaluate the association of MMP9 and MMP14 genetic polymorphisms with long-term complications of surgical treatment in breast cancer patients. Methods: The study included 99 breast cancer patients treated with either 75 or 37.5 mg of tramadol for pain relief after axillary breast cancer surgery as part of a randomized clinical trial KCT 04/2015-DORETAonko/si at Institute of Oncology Ljubljana. All patients were genotyped for MMP9 polymorphisms rs2250889, rs17577, rs17576, and rs20544 as well as MMP14 rs1042703, rs1042704, and rs743257. The association of genetic factors with long-term complications was evaluated using logistic regression. Results: One year after surgery, 24 (24.2%) patients had lymphedema, 25 (25.3%) experienced neuropathic pain and 21 (21.1%) experienced chronic pain. Carriers of polymorphic MMP9 rs2250889 allele experienced significantly more lymphedema compared to carriers of two wild-type alleles (OR = 3.45, 95% CI = 1.10-10.84, P = 0.034), even after adjustment for tramadol dose (OR = 3.76, 95% CI = 1.16-12.18, P = 0.027). Carriers of polymorphic MMP14 rs1042704 allele experienced more neuropathic pain compared to carriers of two wild-type alleles (OR = 3.21, 95% CI = 1.26-8.20, P = 0.015), even after adjustment for tramadol dose (OR = 3.80, 95% CI = 1.42-10.17, P = 0.008). Conclusions: MMP genetic variability was associated with long-term complications after axillary surgery in breast cancer patients, suggesting that MMPs may have an important role as modulators of wound healing.

Bisphosphonate-functionalized hyaluronic acid showing selective affinity for osteoclasts as a potential treatment for osteoporosis

2015 ◽  
Vol 3 (8) ◽  
pp. 1197-1207 ◽  
Author(s):  
Sujit Kootala ◽  
Dmitri Ossipov ◽  
Jeroen JJP van den Beucken ◽  
Sander Leeuwenburgh ◽  
Jöns Hilborn
Keyword(s):  
Hyaluronic Acid ◽  
Potential Treatment ◽  
Term Administration ◽  
High Doses

Bisphosphonate-functionalized hyaluronic can potentially reduce long-term administration of high doses of BPs.

F625 DOES LONG-TERM ADMINISTRATION OF GABAPENTIN OR PAROXETINE REDUCE NEUROPATHIC PAIN IN A RODENT MODEL?- A PLACEBO CONTROLLED STUDY

2011 ◽  
Vol 5 (S1) ◽  
pp. 176-176
Author(s):  
C. Darabi ◽  
T. Rouwette ◽  
J. Van Zundert ◽  
R. Heylen ◽  
T. Kozicz ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Rodent Model ◽  
Controlled Study ◽  
Term Administration

F629 DOES LONG-TERM ADMINISTRATION OF AMITRIPTYLINE OR MORPHINE REDUCE NEUROPATHIC PAIN IN A RODENT MODEL?- A PLACEBO CONTROLLED STUDY

2011 ◽  
Vol 5 (S1) ◽  
pp. 177-177
Author(s):  
A. Darabi ◽  
T. Rouwette ◽  
J. Van Zundert ◽  
R. Heylen ◽  
T. Kozicz ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Rodent Model ◽  
Controlled Study ◽  
Term Administration

scholarly journals Long-term interleukin-6 administration stimulates sustained thrombopoiesis and acute-phase protein synthesis in a small primate-- the marmoset

Blood ◽  
1994 ◽  
Vol 83 (8) ◽  
pp. 2093-2102
Author(s):  
B Ryffel ◽  
BD Car ◽  
G Woerly ◽  
M Weber ◽  
F DiPadova ◽  
...  
Keyword(s):  
Acute Phase ◽  
Interleukin 6 ◽  
Neutralizing Antibodies ◽  
Acute Phase Protein ◽  
Acute Phase Protein Response ◽  
Phase Protein ◽  
Term Administration ◽  
High Doses ◽  
Protein Response

Interleukin-6 (IL-6) has been ascribed significant roles in both hematopoiesis and the immune response, although its contribution to host defence as a whole is poorly understood. Because short-term IL-6 treatment was previously shown to stimulate megakaryocytopoiesis, we investigated the effect of long-term administration of IL-6 on megakaryocytopoiesis and other systemic parameters in nonhuman primates. We chose a small primate, the marmoset (Callithrix jacchus), which enabled long-term administration at high doses. Recombinant human IL-6 (rhIL-6) administered at doses of up to 1,000 micrograms/kg/d over 4 and 9 weeks caused a sustained twofold to threefold increase of thrombocyte counts, peaking at 4 weeks. Thrombocyte counts declined thereafter, despite continuing IL-6 administration. The number of bone marrow megakaryocytes at 4 and 9 weeks was not increased compared with controls, but the ploidy grade was augmented, suggesting that IL-6 effects are restricted to mature megakaryocytes in vivo. An acute-phase protein response was observed within 24 hours after the first IL-6 administration and reached a maximum after 1 week of IL-6 administration at 25 micrograms/kg. Serum C-reactive protein, haptoglobin, and ceruloplasmin were increased, whereas albumin and transferrin levels declined. The acute-phase protein response was not associated with any morphologic evidence of hepatocellular damage. The increased levels of Ig and soluble IL-2 receptor in the serum levels reflected systemic immunostimulation. There was no evidence of renal mesangioproliferative pathology. Antibodies against rhIL-6 developed within 2 weeks, continuously increasing during the course of the study. High titers of neutralizing antibodies appeared concomitantly with the decrease in platelet counts and decline in acute-phase proteins. Therefore, despite the pleiotropic effects of IL-6 observed in vitro, long-term administration of IL-6 caused a selective and sustained stimulation of thrombopoiesis in marmosets that was only ablated by the appearance of neutralizing antibodies, and high doses were well tolerated in marmosets. A long-term targeting of IL-6 to cells of the megakaryocytic lineage, without evoking general toxicity, confirms the potential therapeutic usefulness of rhIL-6 for the chronic treatment of thrombocytopenic patients.

scholarly journals INFLUENCE OF LONG-TERM CYTOTOXIC CHEMOTHERAPY ON THE CONDITION OF PERIPHERAL VENOUS CHANNEL

2017 ◽  
Vol 3 ◽  
pp. 49-55
Author(s):  
Tetiana Tkachuk
Keyword(s):  
Cancer Patients ◽  
Vascular Access ◽  
Venous Access ◽  
Term Treatment ◽  
Cytotoxic Chemotherapy ◽  
Cytotoxic Therapy ◽  
Qualitative And Quantitative ◽  
Long Term Treatment ◽  
Term Administration

The necessity of long-term venous access in cancer patients appears at frequent and long-term courses of cytotoxic therapy. Peripheral veins of forearms are most often used for these aims. The conditions of peripheral venous channel in 32 cancer patients, who underwent the long-term treatment with antitumor preparations were analyzed in the article on own investigatory material. The methods of dopplerography, morphological and immunohystochemical studies were used. The qualitative and quantitative dopplerographic changes in forearm veins in different terms after chemotherapy start were revealed in most patients. The conclusion was made about unsuitability of forearm peripheral veins for the long term administration of cytostatics and the necessity to create the alternative vascular access that would correspond to the criteria of safety, reliability and long-term exploitation.

Sign in / Sign up

Export Citation Format

Share Document